Clinical Trial Update: A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy [Phase 2]

View source ↗

Summary

Phase 2 multicenter study evaluating hetrombopag to prevent thrombocytopenia caused by lung cancer therapy; recruitment has not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Hetrombopag (hetrombopag)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING